Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Equifax reports tomorrow morning with three datasets pointing the same direction, and a fourth pointing the other way.
Earnings are due October 20. Short interest has collapsed 31% in one week to 4.1% of the free float. The put/call ratio hit 1.45 on Thursday, more than two standard deviations below its 20-day mean of 1.93. Those two reads agree: the bearish positioning that defined most of the quarter is gone.
The analyst community is less convinced.
Oppenheimer's Rayna Kumar downgraded Equifax to Perform from Outperform on October 16, citing mortgage headwinds and margin pressure. She offered no price target. That downgrade sits alongside a wave of target cuts: RBC Capital trimmed to $177 from $194 on the same day, Morgan Stanley went to $205 from $225 on October 13, and Needham cut to $190 from $245. Barclays dropped its target to $155 from $200 on October 2.
The consensus remains at Buy, with 12 buys against 6 holds and a mean price target of $196.35. At Friday's close of $161.25, that implies 22% upside. But the direction of analyst revisions over the past three weeks has been consistently lower, and the EPS momentum score ranks in the 18th percentile over 30 days.
The bear case is straightforward: mortgage origination volumes are under pressure, international growth is slowing, and the 2017 data breach continues to carry reputational and legal costs. The bull case rests on income and employment verification adoption, price increases in FICO scores, and the expectation of margin expansion once mortgage volumes recover.
Short interest stood at roughly 7.4 million shares in early October. It now sits at just over 5 million. The borrow market is exceptionally loose: availability has risen 70% over the past week to 5,797%, meaning there are nearly 58 shares available to lend for every one currently borrowed. Cost to borrow is 0.35%, down 18% on the week. Shorts are covering by choice, not because the lending market is forcing them out.
The put/call ratio at 1.45 is near the bottom of its 52-week range of 0.50 to 2.21. After weeks above 2.0, the single-session drop on October 16 is a clean pivot. Traders who were paying for downside protection through the quarter moved toward calls in the session before the earnings announcement window opened.
One additional data point sits further out. ORTEX puts the probability of Equifax joining the CRSP US Small index at 70% in the December 2026 quarterly review. The stock needs to close above $179.69 to qualify. That would require an 11.4% gain from Friday's close. The rank date is December 4. If the threshold is reached, index trackers would need to buy an estimated $302 million of stock, equivalent to 1.1 days of normal trading volume, on December 22.
See the live data behind this article on ORTEX.
Open EFX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
